The AI Rout Paid the Toll Booths: CME +3.4% and Nasdaq +7.5% While the Composite Fell 2.6%

The selloff was narrow and mechanical: a mega-cap platform guided AI infrastructure spending higher while turning free cash flow negative for the first time in a decade, and an automaker trimmed its 2026 capital plan. The Philadelphia Semiconductor Index fell 6.72% in one session, roughly a quarter of everything it had gained since its June 22 record close, and about $800 billion of market value came off a handful of megacaps. On the same day, CME Group closed up 3.45% and Nasdaq closed up 7.47%. Because a venue is paid for hedging demand and recurring licences rather than for capital spending, the rout converted volatility into revenue for the exchanges while it destroyed the earnings expectations of the chip complex.

CME's third quarter is the cleanest evidence that the toll booth gets paid in a capex scare. Revenue of $1,737.3 million was the highest third quarter in the company's history, 13.0% above a year earlier, and average daily volume of 29.4 million contracts was a record for any third quarter. Interest rates alone supplied 51% of that volume, and open interest reached 128 million contracts at September 30 — the highest September-end open interest in CME's history — before rising further to 133 million in October.

Here is what the headline leaves out. CME's \"record third quarter\" of $1,737.3 million was still 7.6% below the $1,880.1 million booked in the first quarter of 2026, and only 1.8% above the second quarter. A record third quarter is a comparison against the same three months a year earlier, not a new peak for the business. That matters for the $367 target, which requires volumes to stay at record levels for another four quarters while the shares already trade on about 25 times trailing earnings of $12.19.

Nasdaq's third quarter looks like a different business from CME's. Net revenue of $1.48 billion rose 13% reported and 14% organic, solutions revenue reached $1.17 billion and now makes up 79% of the total, and annualised recurring revenue reached $3.37 billion, up 12% reported and 14% organic. The exchange's own trading and clearing business grew 2%, with market services net revenue of $309 million. The mix shift left four-fifths of Nasdaq's revenue outside the trading cycle, which is what makes the stock behave like infrastructure rather than like a beta trade.

A venue is a toll booth with two sides, and both sides show up in the tape. Upstream is the liquidity and the order flow it resells. Downstream is the licensing, listing and data revenue it collects from the firms that need the market to exist. The re-rating only holds if both sides keep paying.

CME's crypto business is the clearest example of a venue monetising a new asset class, and it is where the cross-industry bill shows up. Cryptocurrency trading went 24 hours a day on May 29, 2026, and since then more than 361,000 contracts worth about $3.7 billion have traded, averaging just over 20,000 contracts and $206 million per weekend. Bitcoin Cash and Uniswap futures were slated to start on Oct 19, 2026.

CME closed at $305.98 on Oct 22, up 3.45%, taking its market value to about $110.0 billion — the highest in the past year — and putting the shares on about 25 times trailing earnings of $12.19. Nasdaq closed at $103.30, up 7.47% and also a 52-week high, on about 28 times trailing earnings of $3.66. Neither is cheap, and the two have very different failure modes.

The downside case is simple, and it is already visible in the numbers. CME's third-quarter revenue was 7.6% below its own first-quarter peak, and adjusted EPS of $3.02 came in only about 1% above the $2.99 consensus — the kind of beat a company delivers when it is already running at record volume. If the chip complex stabilises and the VIX settles near 18.25, record average daily volume becomes the peak rather than the run rate, and a 0.27 beta offers no protection from a multiple reset.

The venues are not a hedge against the AI trade; they are the other side of it. When megacap spending plans wobble, hedging demand, index licensing and listing demand all rise together, and the two operators that monetise that on fixed cost bases convert a 13% revenue increase into a 16% earnings increase. CME is the higher-beta expression: JPMorgan's $367 target is 20% above the Oct 22 close, but it needs record volumes for another four quarters while the shares already trade near 25 times trailing earnings. Nasdaq is the better compounding asset — $3.37 billion of recurring revenue growing 14% organically, a 23-hour trading day and an equity token inside the next eighteen months — at the cost of one line that is a direct claim on the equity market that just fell 2.58%.